BHP Group Ltd Succession Spotlight Sharpens as Geraldine Slattery Emerges in Twin CEO Race

BHP Group Ltd Succession Spotlight Sharpens as Geraldine Slattery Emerges in Twin CEO Race

March 10, 2026

Melbourne, March 11, 2026, 08:41 AEDT.

Geraldine Slattery, BHP Group Ltd’s Australia President, is suddenly at the heart of not one but two high-profile CEO succession talks. The Australian, on March 11, flagged her as a frontrunner inside BHP to take over from Chief Executive Mike Henry down the line. Just days before, Reuters reported (March 8) that Slattery’s name is also circulating as a candidate for the open CEO spot at Woodside Energy. The Australian

This is significant at the moment, with Slattery overseeing BHP’s Australia division—covering iron ore, copper, nickel, and coal. A departure here would disrupt one of BHP’s top operating posts, right as the miner sharpens its focus on copper growth. The next quarterly production numbers land April 22. BHP

Woodside isn’t saying anything about the speculation, but the company has set plans to name a permanent CEO in the first quarter of 2026. According to Reuters, acting CEO Liz Westcott is in the mix with two other internal candidates. The West, reporting March 11, said interviews had started. Reuters

BHP hasn’t responded publicly to the most recent round of succession talk. Back in May 2025, Reuters reported that BHP’s internal talent pool ran deeper than Rio Tinto’s. The report put Slattery, along with CFO Vandita Pant, at the top of the internal contenders list. Investors, it noted, were fans of Slattery’s operational track record—especially after her stint running BHP’s petroleum division. Reuters

Who takes the helm at BHP is up in the air—and it couldn’t come at a trickier moment for the miner. Back in February, BHP reported a 22% jump in first-half underlying attributable profit, hitting $6.2 billion. Copper, for the first time, made up 51% of operating earnings, nudging past iron ore. Reuters

Mike Henry leaned on that update to make BHP’s priorities clear. “Growth in copper and potash” is on the agenda, he said. Portfolio and asset management, he added, have the potential to free up as much as $10 billion in value. BHP

Rio Tinto wrapped up its transition last year, handing the CEO role to insider Simon Trott. BHP, though, hasn’t settled its succession plan yet—a live question as major miners chase fresh copper supplies. Reuters

Back in January, MST Marquee analyst Saul Kavonic told the Australian Financial Review that Woodside’s incoming CEO might require “a more commercial background.” That lines up with Slattery’s resume—she led BHP’s petroleum unit before the merger with Woodside. Australian Financial Review

Still, things could change fast. Woodside might tap someone from inside, Slattery might remain at BHP, and with iron ore negotiations in China heating up—not to mention major outlays in potash and copper—BHP’s board may opt for a slower approach. Reuters

Succession has surged back into focus for BHP, after recent reporting reignited debate over its leadership. Copper, now outstripping iron ore in profit, has shifted the stakes for whoever steps in next—and the impact will stretch far past Melbourne. Reuters

Marcin Frąckiewicz

Marcin Frąckiewicz is the CEO of TS2 Space and a longtime technology entrepreneur focused on telecommunications, satellite communications and digital innovation. A graduate of the Warsaw School of Economics (SGH), he writes about space technology, artificial intelligence and publicly traded technology companies. His analysis covers major market trends, emerging technologies and the businesses shaping the future of the global economy.

Stock Market Today

  • AstraZeneca Shares Show Valuation Disparities Amid Pipeline Optimism
    June 26, 2026, 7:54 PM EDT. AstraZeneca (LSE:AZN) shares gained 1.8% recently, with a 7-day return of 8.19% and a one-year total shareholder return of 42.48%, reflecting strong momentum. Trading at £143.18, the stock shows a 38.06% intrinsic discount against a fair value estimate of £164.85 based on future cash flows, signalling potential undervaluation. The company's diversified late-stage pipeline, especially in oncology and rare diseases, forecasts over $10 billion in peak risk-adjusted revenue, supporting long-term growth. However, risks include reliance on blockbuster drugs and increasing government price controls. Notably, AstraZeneca's price-to-earnings ratio (28.2x) surpasses the industry average (21.3x), highlighting mixed valuation signals between cash flow models and earnings multiples. Investors face a key question: weigh discounted cash flows or premium earnings multiple in assessing the stock's fairness.